Lakewood-Amedex Biotherapeutics reports release available on Nu-3 gel preclinical safety data
LABT•Planned Phase 2a study in infected diabetic foot ulcers
The company is preparing a Phase 2a study in infected diabetic foot ulcers using 2%, 5%, and 10% gel concentrations.
Press release: https://lakewoodamedex.com/
Preclinical safety data support Phase 2a dose selection
Lakewood-Amedex Biotherapeutics posted preclinical safety data supporting dose selection for a planned Phase 2a trial of Nu-3 gel.
Nu-3 was well tolerated at doses above planned Phase 2a levels, with very low systemic exposure.
